Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 ...

The US FDA has approved the drug Mitapivat, marketed as Aqvesme, as the very first oral therapy for anemia in adults with ...

OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif., January 05, 2026--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist") announced the submission of a New Drug ...

Artificial intelligence to speed diagnosis, switching complement therapies, ravulizumab during pregnancy, and iptacopan ...

This population-based study shows that shared and pattern-specific blood biomarkers reflect biological vulnerability ...

Possible Reasons, and The Best Labs for Fatigue Key Takeaways: Fatigue describes more than just feeling sleepy — it’s a ...

The US FDA has greenlit Mitapivat, the first oral treatment for anaemia in adults with thalassemia, marking a significant advancement in thalassemia care.

FDA expands Accrufer approval to treat iron deficiency in pediatric patients aged 10 years and older based on phase 3 FORTIS trial outcomes.

Interventional cardiologists say some cases that coders flag and submit to the NCDR aren’t in fact problematic.

Supplements like berberine, cinnamon, ginseng, and St. John’s Wort can affect how diabetes medications work. Learn the ...

Researchers compared the safety and efficacy of BrECADD vs eBEACOPP, a standard regimen, in the newly diagnosed, advanced-stage classical HL setting. Researchers determined the BrECADD combination ...

MASI's strong Q3 2025 results, FDA clearance and partnerships fuel growth hopes, but SET dependence and reimbursement risks ...